Market volatility in tech has narrowed, and SLXN stock forecast models now highlight a beta of 1.12, implying moderate sensitivity to broader market swings while preserving relative stability. Discover Silexion Therapeutics' earnings and revenue growth rates, forecasts , and the latest analyst predictions while comparing them to its industry peers. Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, which are common oncogenic drivers in human cancers. The company is advancing its next-generation siRNA candidate, SIL204, and has shown promising results in preclinical studies. By tracking SLXN stock forecast correlation with index movements, analysts suggest potential sector-led momentum could elevate price targets by 8–10% in the upcoming earnings season.